Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Jemincare Out-licenses Prostate Cancer Drug to Roche in $650 Million Deal

publication date: Oct 11, 2022

Jinxi Jemincare, a China pharma formed in 1999, out-licensed global rights for its androgen receptor degrader to Roche in a $650 million agreement. JMKX002992 is being developed to treat prostate cancer patients who have developed resistance to current therapies. The oral small molecule candidate, which was developed in Shanghai Jemincare’s 500-scientist R&D center, is currently in preclinical testing. Jemincare will receive $60 million upfront and the rest in milestones, plus royalties. Roche said the agreement was the first global in-licensing between its Genentech subsidiary and a China biopharma. The deal was originally announced in August. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital